Last10K.com

Acelity L.P. Inc. (1557939) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2015

Acelity L.P. Inc.

CIK: 1557939



ACELITY L.P. INC. REPORTS
THIRD QUARTER AND FIRST NINE MONTHS FINANCIAL RESULTS FOR 2015
Total Revenue Grew 3.3% on a Constant Currency Basis


Third Quarter Financial Highlights

Revenue of $477.7 million, down 0.9% as reported on a GAAP basis from the prior-year period and grew 3.3% on a constant currency basis

Revenue from Advanced Wound Therapeutics (“AWT”), down 1.9% as reported on a GAAP basis, grew 3.1% on a constant currency basis, led by mid-single digit volume increases compared to the prior-year period

Revenue from Regenerative Medicine (“RM”) grew 4.5% as reported on a GAAP basis, and 5.9% on a constant currency basis, led by high-single digit increases in revenue related to breast reconstruction procedures

Operating earnings of $106.1 million, up 20.0% as reported on a GAAP basis from $88.3 million in the prior-year period

Adjusted EBITDA from continuing operations1 of $187.5 million, down 2.3% as reported from the prior-year period and grew 0.9% on a constant currency basis, achieving an Adjusted EBITDA margin of 39.2%


Operational Highlights

Reinforced the strategy of geographic expansion with double-digit growth in advanced wound dressings, driven by strong performance in markets outside the U.S. In addition, Acelity entered into a strategic commercial partnership with GHD GesundHeits GmbH Deutschland (“GHD”) to distribute Acelity’s advanced wound dressings portfolio in Germany. The partnership with GHD, the largest provider of homecare services in Germany, offers Acelity access to serve GHD’s breadth of customers in both acute and post-acute care settings.

Expanded our product offerings in Brazil by obtaining approval to sell StratticeTM, an acellular reconstructive tissue matrix designed to assist in soft-tissue procedures to reinforce tissue where weakness exists and promote tissue regeneration.

Expanded Acelity’s industry-leading product portfolio with additions to three renowned brands in order to provide clinicians more options when treating patients— Strattice™ Reconstructive Tissue Matrix Perforated (U.S.), a shorter Prevena™ dressing for smaller, anatomically-challenging incisions (U.S. and Europe) and TIELLE® Silicone Border (Europe), a hydropolymer foam dressing for increased patient comfort with exudate absorption.


Joe Woody, President and Chief Executive Officer, commented, “The execution of our strategy continues to drive momentum for our business and is reflected in our strong performance in the third quarter.

“Our core business continues to deliver solid results led by good volume progression in advanced devices, as well as strength in both Regenerative Medicine and advanced wound dressings. Sales of our expansion products, led by PREVENA™ and REVOLVE™, are at record levels and provide nice diversification to our traditional product offerings. We are investing in our franchise structure to drive more focus towards both organic and inorganic near adjacencies. Outside of the United States, we advanced the development of our global platform with double-digit revenue growth in our emerging markets. These results are a testament to the fact that our portfolio of products continues to meet the needs of a growing, global population. Our presence in



The following information was filed by Acelity L.P. Inc. on Tuesday, October 27, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (loss)
Condensed Consolidated Statements Of Comprehensive Income (loss) (parenthetical)
Condensed Consolidated Statements Of Operations
Accumulated Other Comprehensive Income (loss)
Accumulated Other Comprehensive Income (loss) (details)
Accumulated Other Comprehensive Income (loss) (tables)
Acquisitions And Divestitures (details)
Acquisitions And Divestitures (tables)
Acquisitions And Divestitures Acquisitions And Divestitures
Commitments And Contingencies
Commitments And Contingencies (details)
Derivative Financial Instruments And Fair Value Measurements
Derivative Financial Instruments And Fair Value Measurements (tables)
Derivative Financial Instruments And Fair Value Measurements - Derivative Financial Instruments (details)
Derivative Financial Instruments And Fair Value Measurements - Fair Value And Balance Sheet Locations (details)
Derivative Financial Instruments And Fair Value Measurements - Gain (loss) On Derivatives (details)
Guarantor Condensed Consolidating Financial Statements
Guarantor Condensed Consolidating Financial Statements (tables)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Balance Sheet (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Cash Flow (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Statement Of Operations And Comprehensive Income (loss) (details)
Long-term Debt
Long-term Debt (details)
Long-term Debt (tables)
Segment Information
Segment Information (details)
Segment Information (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Supplemental Balance Sheet Data
Supplemental Balance Sheet Data (tables)
Supplemental Balance Sheet Data - Accounts Receivable, Net (details)
Supplemental Balance Sheet Data - Inventories, Net (details)

Material Contracts, Statements, Certifications & more

Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits

CIK: 1557939
Form Type: 10-Q Quarterly Report
Accession Number: 0001557939-15-000060
Submitted to the SEC: Wed Oct 28 2015 5:01:24 PM EST
Accepted by the SEC: Wed Oct 28 2015
Period: Wednesday, September 30, 2015
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1557939/0001557939-15-000060.htm